The United Kingdom granted authorization for the use of Johnson & Johnson’s single-dose vaccine against COVID-19, which joins the other three preparations already approved, from the pharmaceutical companies AstraZeneca, Pfizer and Moderna.
The British Medicines and Health Products Regulatory Agency (MHRA) announced that the vaccine developed by Janssen, a Johnson & Johnson subsidiary, meets the safety, quality and effectiveness requirements to be supplied to those over 18 years of age.
Encouraging news for society as a whole, MHRA Executive Director June Raine said in a statement, in which she stressed that the agency will continue to work to monitor vaccines in circulation and verify that their benefits continue to outweigh the risks.
The preparation, which can be stored at a temperature between 2 and 8 degrees, demonstrated at the beginning of the year an effectiveness of 67% against coronavirus infections and 85% in the prevention of a serious COVID-19 that causes hospitalizations.
The UK, which is maintaining its goal of vaccinating the entire adult population by the end of July, had initially purchased 30 million doses of Janssen, but reduced the order to 20 million units in response to the good pace of the immunization plan.
“This is a further boost to the UK’s hugely successful vaccination program, which has already saved more than 13,000 lives,” British Health Minister Matt Hancock said in a statement, convinced that the vaccine will play a “role. important “in the coming months.
The British Government is preparing an immunization reinforcement program, of which the details are still unknown, which will be based on clinical need, according to the Ministry of Health in the note released this Friday.
The preparation from the pharmaceutical company Janssen, which is studying the possibility of supplying two doses instead of one, has already received the green light from the European Medicines Agency (EMA), the Food and Drug Administration (FDA) and the World Organization of Health (WHO).